{"id":4856,"date":"2024-04-15T22:55:21","date_gmt":"2024-04-15T14:55:21","guid":{"rendered":"https:\/\/flcube.com\/?p=4856"},"modified":"2024-10-13T19:52:35","modified_gmt":"2024-10-13T11:52:35","slug":"89bio-partners-with-bibio-biopharma-to-build-api-facility-for-pegozafermin-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4856","title":{"rendered":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China"},"content":{"rendered":"\n

U.S. biotechnology company 89bio (NASDAQ: ETNB<\/a>) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio\u2019s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase III development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).<\/p>\n\n\n\n

According to an SEC filing from 89bio, BiBio will receive a payment of USD 135 million for the construction of the new facility dedicated to the commercial supply of pegozafermin. Under the terms of the deal signed in February this year, 45% of the payment is due in Q3 2024, with the remaining amount structured against milestones. BiBio, which operates in both Shanghai and Boston, U.S., will establish the facility in Shanghai\u2019s Lin-gang Special Area, a free-trade zone.<\/p>\n\n\n\n

Last month, 89bio announced the commencement of a Phase III study for pegozafermin targeting non-cirrhotic MASH patients with fibrosis. Additionally, the drug candidate has been granted Priority Medicines (PRIME) status by the European Medicines Agency, indicating its potential to address unmet medical needs.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1068,1069,19,1067,76],"class_list":["post-4856","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-89bio","tag-bibio-biopharma","tag-cro-cmo-cdmo","tag-nasdaq-etnb","tag-nash"],"yoast_head":"\n89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio\u2019s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase III development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4856\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4856\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-15T14:55:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T11:52:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China\",\"datePublished\":\"2024-04-15T14:55:21+00:00\",\"dateModified\":\"2024-10-13T11:52:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856\"},\"wordCount\":199,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"89bio\",\"BiBio Biopharma\",\"CRO \\\/ CMO \\\/ CDMO\",\"NASDAQ: ETNB\",\"NASH\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4856#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4856\",\"name\":\"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-15T14:55:21+00:00\",\"dateModified\":\"2024-10-13T11:52:35+00:00\",\"description\":\"U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio\u2019s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase III development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4856\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4856#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China - Insight, China's Pharmaceutical Industry","description":"U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio\u2019s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase III development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4856","og_locale":"en_US","og_type":"article","og_title":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4856","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-15T14:55:21+00:00","article_modified_time":"2024-10-13T11:52:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4856#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4856"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China","datePublished":"2024-04-15T14:55:21+00:00","dateModified":"2024-10-13T11:52:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4856"},"wordCount":199,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["89bio","BiBio Biopharma","CRO \/ CMO \/ CDMO","NASDAQ: ETNB","NASH"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4856#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4856","url":"https:\/\/flcube.com\/?p=4856","name":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-15T14:55:21+00:00","dateModified":"2024-10-13T11:52:35+00:00","description":"U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio\u2019s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase III development for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4856#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4856"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4856#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4856"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4856\/revisions"}],"predecessor-version":[{"id":6108,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4856\/revisions\/6108"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}